</s><s><s> human papillomavirus ( hpv ) 4 immunogenicity and per-protocol efficacy in females and males aged 9 to 26 years are available from phase 2 and 3 efficacy trials conducted among females aged 16 to 23 years. 
 vaccine produced antibody titers higher than those after natural infection : among females, anti-hpv 6, 11, 16, and 18 geometric mean titers (GMTs ) 1 month after the third dose were higher than that observed in participants who were HPV seropositive and PCR negative at enrollment in the placebo group. among males, no efficacy was observed against external genital lesions or anal intraepithelial neoplasia ( ain ) associated with any of the 10 nonvaccine types evaluated. </s>